Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111682 | 0.81 | HTR7 (0.56) | SIGMAR1HTR7ALDH1A1MAPTKDM4E | |
| SCHEMBL2094246 | 0.81 | CYP2A13 (0.66) | SIGMAR1CYP2A13ALDH1A1MAPTKDM4E | |
| SCHEMBL1111705 | 0.78 | HTR7 (0.43) | SIGMAR1CYP2A13HTR7ALDH1A1KDM4E | |
| SCHEMBL3960480 | 0.77 | CYP2A13 (0.49) | SIGMAR1CYP2A13ALDH1A1MAPTKDM4E | |
| SCHEMBL1578951 | 0.77 | SIGMAR1 (0.66) | SIGMAR1CYP2A13ALDH1A1MAPTKDM4E | |
| SCHEMBL2095163 | 0.75 | KDM4E (0.61) | SIGMAR1CYP2A13ALDH1A1MAPTKDM4E | |
| SCHEMBL1111739 | 0.75 | KDM4E (0.47) | CYP2A13HTR7ALDH1A1MAPTKDM4E | |
| SCHEMBL1111691 | 0.75 | HTR7 (0.56) | CYP2A13HTR7ALDH1A1KDM4ELMNA | |
| SCHEMBL1540384 | 0.74 | KDM4E (0.55) | SIGMAR1HTR7ALDH1A1MAPTKDM4E | |
| SCHEMBL1540385 | 0.74 | KDM4E (0.55) | SIGMAR1HTR7ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | SIGMAR1 2606/4885CYP2A13 4498/4885HTR7 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.